Home
Drugs
Ibrance

Ibrance

Drug

Drug Profile

Ibrance is the brand name of palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination endocrine regimens such as aromatase inhibitors or fulvestrant. The FDA first approved Ibrance on February 3, 2015.

Drug Class: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor
Approval Status: FDA approved; first approved February 3, 2015.
Mechanism of Action: Cyclin-dependent kinase 4/6 (CDK4/6) inhibition.

Brand Names

Ibrance

Indications

\HR-positive, HER2-negative advanced or metastatic breast cancer (with aromatase inhibitor or fulvestrant)\

Related News

Oncology Drug Market Sees Strong Growth Amid Patent Cliffs and Novel Modality Shifts

Jun 05, 2026

Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.

Phase 3 Breast Cancer Trial Data Highlights from Q1 2026

Apr 01, 2026

Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.

Pfizer Plans Obesity Drug Launch Drawing on Viagra Rollout Experience

Mar 08, 2026

Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.

Pfizer Advances Oncology Pipeline with BRAFTOVI Trial Success and HYMPAVZI Expansion

Mar 06, 2026

Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.

Pharma Faces $200-300 Billion Patent Cliff Through 2032 as Blockbusters Lose Exclusivity

Feb 16, 2026

The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT06962969	A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database	COMPLETED
NCT04874025	Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer	COMPLETED
NCT02059213	A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer	COMPLETED	PHASE2